Surrogate Endpoints And FDA’s Accelerated Approval Process
- 1 January 2005
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 24 (1), 67-78
- https://doi.org/10.1377/hlthaff.24.1.67
Abstract
There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential “surrogates” for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention’s safety and efficacy.Keywords
This publication has 11 references indexed in Scilit:
- Some Design Issues in Trials of Microbicides for the Prevention of HIV InfectionThe Journal of Infectious Diseases, 2004
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialThe Lancet, 2003
- Intranasal Mupirocin to Prevent PostoperativeStaphylococcus aureusInfectionsThe New England Journal of Medicine, 2002
- Effect of Breastfeeding and Formula Feeding on Transmission of HIV-1Jama-Journal Of The American Medical Association, 2000
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?JAMA, 1999
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Clarithromycin Therapy for BacteremicMycobacterium aviumComplex DiseaseAnnals of Internal Medicine, 1994
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboThe New England Journal of Medicine, 1991
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989